Non-Gastric Advanced MALT Lymphoma Demonstrated Worse Prognosis Than Gastric MALT Lymphoma Even Treated by Rituximab-Combined chemotherapy.

摘要: Abstract 2815 Backgrounds: Next to diffuse large B-cell lymphoma and follicular lymphoma, extranodal marginal zone of mucosa-associated lymphoid tissue (MALT lymphoma) is the third most common subtype non-Hodgkin9s lymphomas. Their clinical course usually indolent with long-progression free survival (PFS) overall (OS). Because it can involve many sites throughout body, a patient MALT often treated by different strategies, radiation therapy, surgery, or chemotherapy. The aims study are assess characteristics treatment results this one analyze prognostic factors. Patients Methods: Ninety-eight patients consecutively diagnosed an expert hematopathologist from March 2001 October 2008 were reviewed retrospectively. They all underwent standarlized staging program in our hospital. Majority had localized disease. Comparisons performed between gastric non-gastric lymphoma. Prognostic significance various factors for PFS was examined. Statistical analyses OS calculated using Kaplan-Meier estimators. Comparison among categories means log-rank test. Using Cox proportional hazards regression analysis, multivariate analysis about estimated risk Results: 48 males 50 females. Median age 62 years old (range 26 85 old). Only 17 advanced diseases. 52 primary site located stomach, 22 orbit, 8 salivary grand. Ninety-three received some treatment, including radiation, chemotherapy surgery. Mainly, eradication Helicobacter Pylori therapy respectively. All but two disseminated diseases rituximab-combined response rate initial 94%, CR 76%. After median follow-up time 40 months 1 109 months), 3-years 100% 89%, 3-year disease 94% 73%, 95% 82% progression-free at three after treatment. Adverse In shorter associated Discussion: Our indicates that long survival, prone have worse prognosis. H.pilori effective first-line leads favorable term out-come. Rituximab-combined even though rituximab era, may become much better. However, therapeutic strategy still controversial. We need clear up which best. Disclosures: No relevant conflicts interest declare.